Carotid body tumor screening: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{Family tree/start}} {{Family tree | | | | | | | | | | | | A01 | | | |A01= Patient with carotid body tumor}} {{Family tree | | | | | | | | | | | | |!| | | | | }} {{Family tre..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Carotid body tumor}} | |||
{{CMG}}; {{AE}} {{Sahar}} | |||
==Overview== | |||
There is insufficient evidence to recommend routine screening for the carotid body tumor. However, patients who manifested the symptoms before the age of 50 years old, those with a positive family history and those with multiple paragangliomas has been recommended to undergo additional testing. | |||
==Screening== | |||
*There is insufficient evidence to recommend routine screening for the carotid body tumor. However, it has been recommended that the following patients should undergo additional evaluations:<ref name="DavilaChang2016">{{cite journal|last1=Davila|first1=Victor J.|last2=Chang|first2=James M.|last3=Stone|first3=William M.|last4=Fowl|first4=Richard J.|last5=Bower|first5=Thomas C.|last6=Hinni|first6=Michael L.|last7=Money|first7=Samuel R.|title=Current surgical management of carotid body tumors|journal=Journal of Vascular Surgery|volume=64|issue=6|year=2016|pages=1703–1710|issn=07415214|doi=10.1016/j.jvs.2016.05.076}}</ref> | |||
**Patients younger than 50 years of age | |||
**Patients with a positive family history for paraganglioma | |||
**Patients with multiple paragangliomas | |||
{{Family tree/start}} | {{Family tree/start}} | ||
{{Family tree | | | | | | | | | | | | A01 | | | |A01= Patient with carotid body tumor}} | {{Family tree | | | | | | | | | | | | A01 | | | |A01= Patient with carotid body tumor}} | ||
| Line 22: | Line 35: | ||
{{Family tree | | | K01 | | | | K02 |K01= 24-hour urine catecholamines and MRI for biochemical screening|K02=surveillance screening every 5 years}} | {{Family tree | | | K01 | | | | K02 |K01= 24-hour urine catecholamines and MRI for biochemical screening|K02=surveillance screening every 5 years}} | ||
{{Family tree/end}} | {{Family tree/end}} | ||
==References== | |||
{{Reflist|2}} | |||
Revision as of 16:12, 8 April 2019
|
Carotid body tumor Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carotid body tumor screening On the Web |
|
American Roentgen Ray Society Images of Carotid body tumor screening |
|
Risk calculators and risk factors for Carotid body tumor screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Overview
There is insufficient evidence to recommend routine screening for the carotid body tumor. However, patients who manifested the symptoms before the age of 50 years old, those with a positive family history and those with multiple paragangliomas has been recommended to undergo additional testing.
Screening
- There is insufficient evidence to recommend routine screening for the carotid body tumor. However, it has been recommended that the following patients should undergo additional evaluations:[1]
- Patients younger than 50 years of age
- Patients with a positive family history for paraganglioma
- Patients with multiple paragangliomas
| Patient with carotid body tumor | |||||||||||||||||||||||||||||||||||
| History, Physical examination, and evaluation of cnotralateral side | |||||||||||||||||||||||||||||||||||
| Patients with age < 50 years Patients with multiple paraganglioma Patients with a positive family history | The rest of the patients | ||||||||||||||||||||||||||||||||||
| SDHD genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHD mutation | Absence of SDHD mutation | ||||||||||||||||||||||||||||||||||
| SDHC and SDHB genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHC/B mutation | Absence of SDHC/B mutation | ||||||||||||||||||||||||||||||||||
| All the relatives should be evaluated for the presence of paragnaglioma | |||||||||||||||||||||||||||||||||||
| whole-body 18F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas | |||||||||||||||||||||||||||||||||||
| Presence of other paraganglioma | Absence of other paraganglioma | ||||||||||||||||||||||||||||||||||
| 24-hour urine catecholamines and MRI for biochemical screening | surveillance screening every 5 years | ||||||||||||||||||||||||||||||||||
References
- ↑ Davila, Victor J.; Chang, James M.; Stone, William M.; Fowl, Richard J.; Bower, Thomas C.; Hinni, Michael L.; Money, Samuel R. (2016). "Current surgical management of carotid body tumors". Journal of Vascular Surgery. 64 (6): 1703–1710. doi:10.1016/j.jvs.2016.05.076. ISSN 0741-5214.